Robert Azelby

2016

In 2016, Robert Azelby earned a total compensation of $1.9M as Executive Vice President, Chief Commercial Officer at Juno Therapeutics, a 81% decrease compared to previous year.

Compensation breakdown

Non-Equity Incentive Plan$132,800
Option Awards$643,532
Salary$409,413
Stock Awards$252,900
Other$473,580
Total$1,912,225

Azelby received $643.5K in option awards, accounting for 34% of the total pay in 2016.

Azelby also received $132.8K in non-equity incentive plan, $409.4K in salary, $252.9K in stock awards and $473.6K in other compensation.

Rankings

In 2016, Robert Azelby's compensation ranked 5,090th out of 14,075 executives tracked by ExecPay. In other words, Azelby earned more than 63.8% of executives.

ClassificationRankingPercentile
All
5,090
out of 14,075
64th
Division
Manufacturing
1,815
out of 5,488
67th
Major group
Chemicals And Allied Products
577
out of 1,900
70th
Industry group
Drugs
432
out of 1,543
72nd
Industry
Biological Products, Except Diagnostic Substances
74
out of 287
74th
Source: SEC filing on April 21, 2017.

Azelby's colleagues

We found four more compensation records of executives who worked with Robert Azelby at Juno Therapeutics in 2016.

2016

Hans Bishop

Juno Therapeutics

Chief Executive Officer

2016

Steven Harr

Juno Therapeutics

Chief Financial Officer

2016

Hyam Levitsky

Juno Therapeutics

Chief Scientific Officer

2016

Bernard Cassidy

Juno Therapeutics

General Counsel

You may also like